Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia
- Registration Number
- NCT06223919
- Lead Sponsor
- Universidad Nacional de Colombia
- Brief Summary
Background: Mpox is a zoonotic disease caused by the mpox virus (MPXV). It has been endemic in West and Central African countries. However, the soaring number of those has been reported in non-endemic countries since May 2022, making World Health Organization (WHO) declare a global mpox Public Health Emergency of International Concern in July 2022. Those with mpox are primarily young men (96%, and median age of 34 \[interquartile range (IQR):29-41 years\]), and 84% are self-identified homosexual, bisexual, and men who have sex with men (MSM) . Furthermore, about half of these mpox cases with known human immunodeficiency virus 1(HIV-1, hereafter shown as HIV). WHO recommended prioritizing vaccinating those populations as high-risk populations, including those with HIV, since they will be severely ill if infected mpox virus (MPXV). The smallpox vaccine is expected to offer cross-immunity against MPXV. Under these circumstances, WHO included LC16m8 in the recommended vaccine lists for mpox as the product is expected to have cross-efficacy and immunogenicity against MPXV. Additionally, the safety profile was demonstrated in both adults and children, including infants who have low immuno-functions. Given that Colombia has the fifth highest mpox prevalence worldwide, WHO encouraged the authorities to implement vaccine programs while evaluating the safety and efficacy of LC16m8 as collaborative research. Following WHO initiative, this study is being conducted with the collaboration of various experts from Colombia and Japan on a large scale, with vaccine contributions and funding from Japan and Colombia However, the current infection situation differs from six months ago, and there have been few recent cases of MPXV infection in the country.
Primary objective: To determine the efficacy of the replicating attenuated live vaccinia virus vaccine LC16m8 against laboratory-confirmed mpox and safety in a Colombian population with a high risk of being infected with MPXV(See the Inclusion Criteria), by comparing the immediate vaccination group and the delayed vaccination groups to assess safety and tolerability until 180 days after vaccination. Study design: An open randomized deployment study (1:1 Immediate and Delayed vaccination group).
Study population: People at high risk of serious illness if infected with MPXV and those who engage in risk behaviors for acquiring MPXV infection.
- Detailed Description
Hypothesis: LC16m8 is a safe and effective vaccine for high-risk immunocompromised populations, including those living with HIV.
Intervention evaluation plan: Vaccinate with LC16m8 those people randomly assigned to two groups: immediate and deferred vaccination 1:1 with a follow-up period of 180 days to evaluate new cases infected by MPXV.
General design: This research is being carried out within the framework of the mpox vaccination implementation program in Colombia. It comprises the following three complementary components:
* Study section 1: Parallel open sequential randomized controlled trial to evaluate the efficacy of LC16m8 vaccine in preventing MPXV infection.
* Study section 2: Cohort study based on the same population base
* Study section 3: Cohort study compared to real world cohort
STUDY SECTION 1: Participants will receive LC16m8 vaccine within 6 weeks (immediate vaccination) or 6 weeks later (delayed vaccination) after randomization. Both groups will be followed up at 14, 30 and 180 days after vaccination, mainly through phone calls.
The study will compare the incidence of new MPXV infections in the early vaccination group from day 14 to day 42 after vaccination with the incidence of rate at which new MPXV infections occur in the delayed vaccination group from 42 days before to 14 days after vaccination; this comparison will be made from the hazard ratio or proportional hazard model.
Additionally, the immune response, including neutralizing antibody titers, will be evaluated from the day of vaccination (Day 1) to 180 days post-vaccination in 60 participants, who will be selected from a single research center and only belonging to the immediate vaccination group. Two 5 mL blood samples (converted to serum) will be collected from the participants for immunogenicity assessments at the following time points: Days 0, 14 (+/-2), 30 (+/-2), and 180 (+/-7) post-vaccination. Another blood sample for immunogenicity assessment will be collected before the vaccine is administered on Day 0.
Safety events will be intensively sought, especially in the first 14 days after vaccine administration and all those arising within 180 days post-vaccination. Participants will also self-report symptoms through a mobile application designed for this purpose.
STUDY SECTION 2 AND 3 (NESTED STUDIES)
- Study of cohorts supported on the same population base: A total of 1,000 vaccinated individuals, including participants in section 1 of the study, will make up the exposed group. The unexposed group will consist of 4,000 unvaccinated individuals from the same population base (a list of HIV patients with a CD4 count greater than 200 cells/ml and PrEP users). who are patients with HIV and CD4 greater than 200 cells/mm3, and PrEP users. The group of unvaccinated individuals are people who meet the study's criteria but did not agree to be vaccinated or withdrew their consent. We will compare the cumulative incidence of these two groups over a 180-day period. We will obtain information about non-participants and withdrawals from the records at the INS and local health entities. We will use the hazard ratio (HR) to compare these groups, and we will also conduct a propensity score analysis.The objective is to demonstrate the effectiveness and safety of the LC16m8 replicating vaccine against laboratory-confirmed MPXV in a Colombian population at high risk of MPXV infection (see inclusion criteria).
Assumptions:
* A relative risk reduction (RRR) of 75% is assumed to calculate the sample size.
* Confidence level: 95%
* Ratio of vaccinated:unvaccinated: 1:4
* RRR: Risk (Rx) in the unvaccinated group - Rx in the vaccinated group/(Rx) in the unvaccinated group.
The incidence of the event (Mpox case) is considered to be 0.4% per period in the exposed group (I Exp (+)) and 1.6% per period in the unexposed group (I exp (-)), in accordance with the current situation of Mpox infection in Colombia.
Incidence in vaccinated 4/1000 = 0.004 Incidence in unvaccinated 64/4000 = 0.016 RR\*\* = 0.2756 (95% CI: 0.1057 ; 0.7185) \*\*Relative risk (RR): Risk (Rx) in unvaccinated/Rx in vaccinated RAR\*\*\*: -1.2888 (95% CI: -2.247; - 0.3306) RRR= 0.7244 (95% CI: 0.2815; 0.8943) Power: 0.92 where RR is relative risk, RAR is absolute risk reduction and RRR is relative risk reduction.
The Ho could be rejected.
- Cohort study compared to the real-world cohort: There will be no sample size because all the information from the databases will be used in the cohort, so a sample is not necessary since we will take all the subjects in HIV and PrEP programs.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 8686
-
Sex: Males and females 2. Age: ≥18 and ≤ 50 years old 3. Persons must be willing and sign the Informed Consent (I.C.). 4. Any of the following conditions including clinical conditions /manifestation:
- People living with the HIV, with stable infection determined by participant´s being on antiretroviral therapy with a blood CD4+ cell count, ≥ 200 cells/mm3 in the last six months before study enrolment
-
Persons that use PrEP (HIV Pre-exposure prophylaxis).
-
Homosexual, Bisexual, or other men who have sex with men (MSM) with multiple sexual partners. Commercial sex workers (CSW) and partners CSW
-
A female participant is eligible to participate if the participant meets one of the inclusion criteria numbered -1, -2 or -3 above. The participant cannot be pregnant or lactating. Additionally, the female participant must meet one of the following conditions:
- The participant has non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least one year or surgically sterile. OR
- The participant has a childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks before the vaccine administration until at least 2 months after the administration and have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 10 days before vaccination.
- Subjects with an unstable medical condition as determined by their initial medical history, physical examination, or laboratory results 2. Subjects with a terminal disease. 3. Subjects with a medical record of anaphylaxis caused by any of the vaccine's excipients or with previous undesired reactions to other vaccines such us (Allergic reactions, Guillain barre syndrome, Varicella zoster, or shingles). 4. Previous medical record of Mpox. 5. Subjects living with HIV with a CD4+ T cell count of fewer than 200 cells/mm3. 6. Pregnant or breastfeeding woman. 7. Active or medical record of atopic dermatitis or eczema, or with close contact with someone with an active or medical record of atopic dermatitis or eczema. 8. The presence of a skin condition with extensive breaks in the skin, such as burns, impetigo, contact dermatitis, or zoster (shingles), is not likely to heal by the day of vaccination. 9. Using immunosuppressive medications, in eye drops, by mouth, or topically (nasal sprays and inhaled corticosteroids are permissible). 10. Active or past malignancy except for cutaneous basal or squamous cell carcinomas. 11. An Autoimmune disease. 12. History of heart failure with decreased left ventricular ejection fraction (<40%). 13. Medical record of splenectomy. 14. Medical record of solid organ or bone marrow transplantation. 15. Medical record of keloid scar development 16. Psychiatric condition that precludes compliance with the protocol. 17. People who received or plan to receive licensed live vaccines 30 days before or after study vaccination. 18. People who received or planned to receive immunoglobulin or other blood products 60 days before HIV screening. 19. People who received or plan to receive experimental drugs/vaccines 30 days before study vaccination or before study completion. 20. People who received or planned to receive systemic immunosuppressive therapy and radiation therapy 30 days before or after the study vaccination. 21. Use of systemic chemotherapy within five years before the study vaccination. 22. Medical record of smallpox vaccination and/or evidence of scarring at the vaccination site. 23. Allergies to streptomycin sulfate and/or erythromycin lactobionate.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Immediate vaccination LC16m8 This vaccin is a yellowish-yellow dry preparation containing live vaccinia virus (strain LC16m8). When the accompanying solvent is added, it dissolves rapidly to form a clear or slightly cloudy yellowish-red or reddish liquid. The ingredients of this vaccin are contained in 0.5 mL of a solution of this product dissolved in 0.5 mL of the accompanying solvent (20 vol% glycerin-added water for injection). Just one dose of vaccine will be administered according to standardized operating procedure (SOP). Briefly, the vaccine is dissolved with 0.5 mL of a diluent provided. The reconstituted vaccine is usually administered percutaneously at a dose of approximately 0.025 mL by the multiple puncture technique using a bifurcated needle. The number of punctures will be 15 times. Procedures for vaccine administration are described in detail in the SOP. The participant must be observed at the vaccination site for 30 minutes after vaccine administration to observe possible immediate reactions. Delayed vaccination LC16m8 The use of placebo as a control group is essential to scientifically assess the efficacy of vaccines in clinical trials and to obtain reliable evidence in preventing the onset of disease. However, the use of a placebo is unethical. Subjects are at high risk of mpox and must not be given a placebo. Therefore, a design was applied in which the immediate treatment group was evaluated with the delayed group as a control group. A period of six weeks was set aside between the immediate and delayed treatment groups to be used for logistics, such as preparations and delivery of the vaccine in the delayed treatment group. It is ethical, for the same reason, because it prevents inequities based on the abovementioned reasons.
- Primary Outcome Measures
Name Time Method Incidence rate of mpox infection between the immediate versus delayed vaccination groups from day 15 to day 56 post-vaccination of the immediate group. For immediate vaccination group: from days 15th to 56th post vaccination. For delayed vaccination group: from enrollment to the day of vaccination (42 days later) The incidence rate of new cases of mpox (laboratory-confirmed) will be calculated with a 95% confidence interval (CI) based on the Poisson distribution for each vaccination group. The time to the onset of the first occurrence of a confirmed mpox case in the subject will be summarized graphically using the Kaplan-Meier method.
Incidence of adverse events between the vaccination groups up to 6 months post vaccination Proportion of adverse events (serious and non-serious) presented in participants included in the two vaccination groups (immediate and delayed)
Incidence rate of mpox infection between the vaccinated cohort versus the unvaccinated cohort 6 months post vaccination The incidence rate of new cases of mpox (laboratory-confirmed) will be calculated with a 95% confidence interval (CI) based on the Poisson distribution for each cohort. The time to the onset of the first occurrence of a confirmed mpox case in the subject will be summarized graphically using the Kaplan-Meier method.
- Secondary Outcome Measures
Name Time Method Geometric mean of LC16m8 neutralizing titer by helper T lymphocytes (CD4) count in each vaccination group up to 6 months post vaccination Subgroups of patients with a CD4 count of 350 or less and those with a CD4 count greater than 350 will be compared for each vaccination group.
Maximum lesion area (MLA) in mm² after scarification with vaccination LC16m8 up to 6 months post vaccination take area measured 14 days post vaccination
Frequency of laboratory-confirmed severe cases of MPOX in the immediate and delayed vaccination groups. 6 months post-vaccination Proportion of participants with confirmed MPOX that presented severe symptoms requiring hospitalization, emergency department care, or death associated with MPOX.
Incidence rate of mpox suspected cases without laboratory confirmation between the immediate versus delayed vaccination groups from day 15 to day 56 post-vaccination of the immediate group. - For immediate vaccination group: from days 15th to 56th post vaccination. For delayed vaccination group: from enrollment to the day of vaccination (42 days later Mpox suspected cases correspond to participants that present with skin lesions to the emergency room or treating patient.
Proportion of patients with seroconversion of geometric mean neutralizing titer (GMT) of LC16m8. up to 6 months post vaccination Seroconversion is considered in cases where the titer on day 30 is 4 times higher than on day 0.
Geometric mean of LC16m8 neutralizing titer by vaccination group. up to 6 months post vaccination overall geometric mean of each group (immediate and delayed vaccination)
Trial Locations
- Locations (3)
Infecto Clinicos
🇨🇴Bogotá, Colombia
Clinica Universitaria Colombia - Centro Medico Teusaquillo
🇨🇴Bogotá, Colombia
Hospital Universitario San Ignacio
🇨🇴Bogotá, Colombia